Vimarsana
Biggest News Aggregation in the World

Simple Endoscopic Score News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Simple Endoscopic Score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Simple Endoscopic Score Today - Breaking & Trending Today

Redefining IBD Care: Intestinal Ultrasound's Emerging Role in Treat-to-Target Strategies - Vimarsana News

Redefining IBD Care: Intestinal Ultrasound's Emerging Role in Treat-to-Target Strategies

In honor of World Digestive Health Day, this feature examines the growth of intestinal ultrasound in IBD care in the US and how it aligns with STRIDE-II guidance.

Mirikizumab Shows Promise for Moderate to Severe Crohn's - Vimarsana News

Mirikizumab Shows Promise for Moderate to Severe Crohn's

Already approved for ulcerative colitis, the monoclonal antibody mirikizumab met study endpoints for Crohn's disease response and remission.

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024 - Vimarsana News

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024

-Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis-

Upadacitinib Provides Rapid Relief in Crohn's Disease - Vimarsana News

Upadacitinib Provides Rapid Relief in Crohn's Disease

Patients with Crohn's disease achieved rapid symptom relief with upadacitinib, including those with prior biologic failure.

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn's Disease -March 28, 2024 at 04:02 pm EDT - Vimarsana News

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn's Disease -March 28, 2024 at 04:02 pm EDT

Bristol Myers Squibb today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia ...